[FLDM] Fluidigm Corporation


Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization: 282.85 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 7.48 Change: 0.29 (4.03%)
Ext. hours: Change: 0 (0%)

chart FLDM

Refresh chart

Strongest Trends Summary For FLDM

FLDM is in the long-term up 94% above S&P in 1 year and down -73% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company?s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays,

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding29.01 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -3.18% Sales Growth - Q/Q-20.19% P/E
P/E To EPS Growth P/S2.41 P/BV1.99 Price/Cash Per Share2.43
Price/Free Cash Flow-9.42 ROA-13.5% ROE-37.45% ROI-15.7%
Current Ratio6.23 Quick Ratio5.53 Long Term Debt/Equity1.5 Debt Ratio0.17
Gross Margin61.87% Operating Margin-41.94% Net Profit Margin-45.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.73 M Cash From Investing Activities10.07 M Cash From Operating Activities-9.8 M Gross Profit16.08 M
Net Profit-15.93 M Operating Profit-14 M Total Assets395.03 M Total Current Assets155.23 M
Total Current Liabilities24.9 M Total Debt195.51 M Total Liabilities252.58 M Total Revenue26.73 M
Technical Data
High 52 week14.36 Low 52 week4.86 Last close11.72 Last change-3.46%
RSI31.22 Average true range0.68 Beta1.18 Volume281.03 K
Simple moving average 20 days-6.9% Simple moving average 50 days-10.15% Simple moving average 200 days24.09%
Performance Data
Performance Week-4.09% Performance Month-10.19% Performance Quart13.9% Performance Half55.23%
Performance Year102.77% Performance Year-to-date35.96% Volatility daily4.03% Volatility weekly9.01%
Volatility monthly18.47% Volatility yearly63.98% Relative Volume318.24% Average Volume763.07 K
New High New Low


2019-06-17 08:30:00 | Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

2019-06-04 08:30:00 | Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

2019-05-31 17:37:36 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-29 08:45:00 | Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research

2019-05-29 08:30:00 | Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology

2019-05-12 21:47:23 | Hedge Funds Have Never Been This Bullish On Fluidigm Corporation FLDM

2019-05-10 16:05:00 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-09 08:30:00 | Fluidigm to Participate in Upcoming Health Care Investor Conferences

2019-05-06 20:00:00 | Fluidigm Delivers Growth Where It Matters Most in Q1 2019

2019-05-04 09:15:01 | Stocks Soar on Strong Jobs Report; NASDAQ at New High

2019-05-03 14:38:00 | Here's Why Fluidigm Shares Fell as Much as 14.4% Today

2019-05-03 01:24:07 | Fluidigm FLDM Q1 2019 Earnings Call Transcript

2019-05-03 01:07:07 | Edited Transcript of FLDM earnings conference call or presentation 2-May-19 9:00pm GMT

2019-05-02 20:35:12 | Fluidigm FLDM Reports Q1 Loss, Tops Revenue Estimates

2019-05-02 19:25:40 | Fluidigm: 1Q Earnings Snapshot

2019-05-02 16:05:00 | Fluidigm Announces First Quarter 2019 Financial Results

2019-05-02 16:02:00 | Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

2019-05-01 10:26:02 | Masimo Gets CE Mark for ANI Module, Enhances Root Platform

2019-04-30 09:00:00 | Fluidigm Announces 8th Annual Mass Cytometry Summit

2019-04-29 09:41:01 | Can Mass Cytometry Drive Fluidigm's FLDM Q1 Earnings?

2019-04-25 10:34:02 | Fluidigm FLDM May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-04-23 06:00:00 | What to Watch When Fluidigm Reports Q1 Earnings

2019-04-08 15:55:02 | How Should Investors Feel About Fluidigm Corporation's NASDAQ:FLDM CEO Pay?

2019-04-08 14:49:00 | 3 Stocks to Hold for the Next 20 Years

2019-04-05 09:40:01 | Here's Why You Should Invest in DENTSPLY XRAY Stock Now

2019-04-04 16:05:00 | Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results

2019-04-03 10:32:02 | AngioDynamics' ANGO Q3 Earnings & Revenues Lag Estimates

2019-04-02 10:20:02 | AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study

2019-04-02 10:20:02 | Glaukos GKOS Banks on Solid Pipeline Amid Stiff Competition

2019-03-28 08:45:00 | Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research AACR Meeting

2019-03-28 08:30:00 | Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry

2019-03-27 09:42:33 | Look who leased the top floors of South San Francisco's new biotech highrise

2019-03-18 17:48:34 | Fluidigm Corp FLDM Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-15 08:51:12 | Fluidigm FLDM in Focus: Stock Moves 8% Higher

2019-03-14 11:53:00 | Here's Why Fluidigm Rose as Much as 13.4% Today

2019-03-12 09:54:00 | Fluidigm Is Emerging From a Large Base Pattern, So Go Long

2019-03-08 07:47:00 | 3 Top Stocks Under $20

2019-03-05 08:30:00 | Colin McCracken Joins Fluidigm as Chief Commercial Officer

2019-02-22 17:30:00 | Fluidigm to Participate in Upcoming Investor Conferences

2019-02-19 14:00:00 | 3 Top Stocks That Aren't on Wall Street's Radar

2019-02-19 08:00:00 | Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex — What Drives Growth in Today's Competitive Landscape

2019-02-12 19:00:00 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-12 14:23:25 | Fluidigm Corporation NASDAQ:FLDM: Is It A Good Long Term Opportunity?

2019-02-11 17:03:00 | The 1 Stock I'd Buy Right Now

2019-02-08 18:45:13 | Edited Transcript of FLDM earnings conference call or presentation 7-Feb-19 10:00pm GMT

2019-02-08 15:55:00 | Here's Why Fluidigm Rose as Much as 14.2% Today

2019-02-07 20:09:42 | Fluidigm Corp FLDM Q4 2018 Earnings Conference Call Transcript

2019-02-07 18:50:11 | Fluidigm FLDM Reports Q4 Loss, Tops Revenue Estimates

2019-02-07 17:57:36 | Fluidigm: 4Q Earnings Snapshot

2019-02-07 16:05:00 | Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results